Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

British Report Questions Link Between Antiperspirant Use And Cancer

This article was originally published in The Rose Sheet

Executive Summary

Further research should be conducted to determine the role of aluminum in the development of human breast cancer, according to a British report published in the May/June issue of the Journal of Applied Toxicology

You may also be interested in...



Parabens Tentative Amended Final Report Issued By CIR

The Cosmetic Ingredient Review Expert Panel is initiating a 90-day comment period on a tentative amended final safety assessment for parabens, which the panel issued during its Dec. 12-13 meeting in Washington, D.C

Methylparaben Accumulation Noted In UK Breast Tumor Study

Additional research, including studies measuring the levels of parabens in healthy breast tissue, is needed to evaluate the possible connection between the cosmetics preservatives and breast cancer, according to a British study published in the January issue of the Journal of Applied Toxicology

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel